BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6097269)

  • 1. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
    Unger T; Fleck T; Ganten D; Lang RE; Rettig F
    Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Schölkens BA; Becker RH; Kaiser J
    Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Becker RH; Schölkens BA; Metzger M; Schulze KJ
    Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
    Bünning P
    Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.
    Unger T; Ganten D; Lang RE; Schölkens BA
    J Cardiovasc Pharmacol; 1985; 7(1):36-41. PubMed ID: 2580148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
    Metzger H; Maier R; Sitter C; Stern HO
    Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.
    Moursi MG; Ganten D; Lang RE; Unger T
    J Hypertens Suppl; 1986 Oct; 4(3):S495-8. PubMed ID: 3023591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].
    Unger T; Moursi MG; Lebrun C; Ganten D; Lang RE
    Arch Mal Coeur Vaiss; 1986 Jun; 79(6):971-4. PubMed ID: 3026275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
    Unger T; Ganten D; Lang RE; Schölkens BA
    J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
    Witte PU; Metzger H; Eckert HG; Irmisch R
    Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
    Felder K; Witte PU
    Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).
    Unger T; Moursi M; Ganten D; Hermann K; Lang RE
    J Cardiovasc Pharmacol; 1986; 8(2):276-85. PubMed ID: 2422465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Teetz V; Geiger R; Henning R; Urbach H
    Arzneimittelforschung; 1984; 34(10B):1399-401. PubMed ID: 6097264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
    Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
    Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
    Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine.
    Hajdú P; Schmidt D; Bomm M; Hack L; Keller A
    Arzneimittelforschung; 1984; 34(10B):1431-5. PubMed ID: 6097270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
    Gohlke P; Urbach H; Schölkens B; Unger T
    J Pharmacol Exp Ther; 1989 May; 249(2):609-16. PubMed ID: 2542535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General pharmacology of ramipril.
    Omosu M; Komine I; Becker RH; Schölkens BA
    Arzneimittelforschung; 1988 Sep; 38(9):1309-17. PubMed ID: 2975947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
    Caspritz G; Alpermann HG; Schleyerbach R
    Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.